Scholarlink

Objective <p>This investigation aimed to assess the applicability of fertility-sparing surgery (FSS) for early-stage ovarian clear cell carcinoma (OCCC) while examining the clinical requirements for lymph node dissection and adjuvant chemotherapy.</p> Subjects <p>A total of 849 stage I patients were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Survival outcomes were evaluated through Kaplan–Meier methodology for both overall survival (OS) and disease-specific survival (DSS). Prognostic determinants were examined using multivariate regression modeling.</p> Results <p>Among the 849 patients, 84.3% (716 cases) underwent hysterectomy, and 15.7% (133 cases) received FSS. No significant difference was found in OS (90.6% vs. 87.2%, <i>P</i> = 0.257) or DSS (91.6% vs. 87.7%, <i>P</i> = 0.302) between FSS and hysterectomy cohort. Tumor diameter &gt; 10&#xa0;cm, stage IC and lymphadenectomy were independent prognostic factors for patients with stage I OCCC. Among patients with a tumor diameter ≤ 10&#xa0;cm, those who underwent FSS had better OS (97.9% vs. 88.3%, <i>P</i> = 0.034) and DSS (97.9% vs. 88.3%, <i>P</i> = 0.044) than those who received hysterectomy. In stage IA patients, there were no significant differences in prognosis between the two operations. Neither lymphadenectomy nor chemotherapy did not demonstrate superior prognosis in the FSS cohort, whereas chemotherapy was associated with inferior OS (93.5% vs. 84.9%, <i>P</i> = 0.007) and DSS (93.5% vs. 85.5%, <i>P</i> = 0.007) in the hysterectomy cohort.</p> Conclusion <p>For patients with stage IC OCCC and a tumor diameter &gt; 10&#xa0;cm, the selection of FSS should be approached with caution. Given the limitations of the SEER database, larger-scale prospective cohort studies are required to validate the influence of lymphadenectomy and postoperative adjuvant chemotherapy on the prognosis of patients undergoing FSS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic comparison of fertility-sparing surgery and hysterectomy in early-stage ovarian clear cell carcinoma: a population-based analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月19日

查看全文
  • Ying Ning,
  • Xiaonuo Xu,
  • Xinyan Gao,
  • Yan Kong,
  • Xiangyu Liu,
  • Yan Wang,
  • Ke Lei,
  • Tian Tian,
  • Zhumei Cui

摘要

Objective

This investigation aimed to assess the applicability of fertility-sparing surgery (FSS) for early-stage ovarian clear cell carcinoma (OCCC) while examining the clinical requirements for lymph node dissection and adjuvant chemotherapy.

Subjects

A total of 849 stage I patients were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Survival outcomes were evaluated through Kaplan–Meier methodology for both overall survival (OS) and disease-specific survival (DSS). Prognostic determinants were examined using multivariate regression modeling.

Results

Among the 849 patients, 84.3% (716 cases) underwent hysterectomy, and 15.7% (133 cases) received FSS. No significant difference was found in OS (90.6% vs. 87.2%, P = 0.257) or DSS (91.6% vs. 87.7%, P = 0.302) between FSS and hysterectomy cohort. Tumor diameter > 10 cm, stage IC and lymphadenectomy were independent prognostic factors for patients with stage I OCCC. Among patients with a tumor diameter ≤ 10 cm, those who underwent FSS had better OS (97.9% vs. 88.3%, P = 0.034) and DSS (97.9% vs. 88.3%, P = 0.044) than those who received hysterectomy. In stage IA patients, there were no significant differences in prognosis between the two operations. Neither lymphadenectomy nor chemotherapy did not demonstrate superior prognosis in the FSS cohort, whereas chemotherapy was associated with inferior OS (93.5% vs. 84.9%, P = 0.007) and DSS (93.5% vs. 85.5%, P = 0.007) in the hysterectomy cohort.

Conclusion

For patients with stage IC OCCC and a tumor diameter > 10 cm, the selection of FSS should be approached with caution. Given the limitations of the SEER database, larger-scale prospective cohort studies are required to validate the influence of lymphadenectomy and postoperative adjuvant chemotherapy on the prognosis of patients undergoing FSS.